STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?-Reference-Cited by-同舟云学术

STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?

Published:2019-05-29 Issue:5 Volume:24 Page:1138-1148
ISSN:1091-255X
Container-title:Journal of Gastrointestinal Surgery
language:en
Short-container-title:J Gastrointest Surg

Author:

Lopez-Aguiar Alexandra G.^ORCID,Postlewait Lauren M.,Ethun Cecilia G.,Zaidi Mohammad Y.,Zhelnin Kristen,Krasinskas Alyssa,Russell Maria C.,Kooby David A.,Cardona Kenneth,El-Rayes Bassel F.,Maithel Shishir K.

Funder

National Center for Advancing Translational Sciences

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s11605-019-04261-6.pdf

Reference31 articles.

1. Fraenkel, M., et al., Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer, 2014. 21(3): p. R153–63.

2. Niu, G., et al., Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 2002. 21(13): p. 2000–8.

3. Wei, D., et al., Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene, 2003. 22(3): p. 319–29.

4. Crawford, Y. and N. Ferrara, VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res, 2009. 335(1): p. 261–9.

5. Masoumi Moghaddam, S., et al., Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev, 2012. 31(1–2): p. 143–62.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatic neuroendocrine tumor progression and resistance to everolimus: the crucial role of NF-kB and STAT3 interplay;Journal of Endocrinological Investigation;2023-10-26

2. Cancer-Associated Fibroblasts Induce Proliferation and Therapeutic Resistance to Everolimus in Neuroendocrine Tumors through STAT3 Activation;Neuroendocrinology;2022-12-06

3. Treatment personalization in gastrointestinal neuroendocrine tumors;Current Treatment Options in Oncology;2021-02-27

4. Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms;International Journal of Molecular Sciences;2019-10-08